STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
STAT
JANUARY 14, 2025
billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. The FTC noted in its report that so-called specialty generic drugs represent a large and growing amount of spending by plan sponsors and patients.
Let's personalize your content